CYTOKINETICS INC
CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup
Callos Andrew (EVP, Chief Commercial Officer) sold 14,000 shares of CYTOKINETICS INC (CYTK) at $79.88 ($1.12M total) on 2026-07-30 under a Rule 10b5-1 trading plan.
Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).
Over the past 7 days, alphai's AI scored 1 news story mentioning CYTK (CYTOKINETICS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CYTK coverage spans insider activity, regulation and earnings.
In the last 30 days, CYTK insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($2.6M). The most active reporter was Blum Robert I, President & CEO, with 3 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
New commercial traction for MYQORZO and positive Phase 3 topline for aficamten in nHCM are likely to re-rate near-term probability-weighted value, while the large cash raise funds expansion.
This is a routine, pre-arranged insider sale disclosure, not an earnings or guidance catalyst.
UK regulatory approval plus NICE guidance is a concrete commercialization milestone that can improve near-term revenue visibility and sentiment for CYTK’s aficamten program.
UK dual regulatory and reimbursement clearance should expand addressable demand and support a faster NHS rollout versus prior access constraints.
Insider open-market sale by the CEO, even under a 10b5-1 plan, can modestly affect near-term sentiment but is not a fundamental change by itself.
alphai scores every news story that mentions CYTK with an AI model for sentiment and relevance, and aggregates insider trades from CYTOKINETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup
6 min readCallos Andrew (EVP, Chief Commercial Officer) sold 14,000 shares of CYTOKINETICS INC (CYTK) at $79.88 ($1.12M total) on 2026-07-30 under a Rule 10b5-1 trading plan.
2 min readCytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).
4 min readCytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.
4 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $80.87 ($0.61M total) on 2026-07-27 under a Rule 10b5-1 trading plan.
2 min readCytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.
6 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $82.02 ($0.62M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
1 min readCytokinetics (Nasdaq: CYTK) said three late-breaking abstracts were accepted for the ESC Congress 2026 in Munich (Aug 28–31). The company will present primary results from its Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive HCM, plus two other late-breaking studies. Cytokinetics plans an in-person/virtual investor event to discuss the presentations.
2 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $84.92 ($0.64M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readCallos Andrew (EVP, Chief Commercial Officer) sold 15,000 shares of CYTOKINETICS INC (CYTK) at $85.80 ($1.29M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min read
